$GCTK News

Last published 2w ago

2w agoGCTKGlucotrack, Inc. Announces Reverse Stock SplitBusiness Wire1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a healthcare technology and
4w agoGCTKQare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 MedicationsBusiness WireNow free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that Lōkahi believes may become a
1mo agoGCTKLōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität PaderbornBusiness WireCross-border initiative expands Lōkahi's university network, increases capacity for additional revenue generating strategic partnerships, and brings together U.S. and German students to identify and evaluate
1mo agoGCTKLōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14Business WireDeveloped Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow Lōkahi Therapeutics™, a
1mo agoGCTKLōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™Business WireLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the
1mo agoGCTKGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingBusiness WireGlucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced the pricing of a "best efforts" public offering of 169,388 shares of common stock at a price of $2.04 per share
1mo agoGCTKLōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating PlatformBusiness WireInnovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development Lōkahi Therapeutics™ Inc.,
1mo agoGCTKLōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development PrioritiesBusiness WireLōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated
1mo agoGCTKLōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma TalentBusiness WireLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for
2mo agoGCTKGlucotrack Announces $11.5 Million FinancingBusiness WireGlucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including
2mo agoGCTKLōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business DivisionsBusiness Wireai² Pipeline™, ai² Talent™, and ai² Accelerator™ create potential revenue-generating opportunities while strengthening Lōkahi's therapeutic development platform. Lōkahi Therapeutics™ Inc., a subsidiary of
2mo agoGCTKLōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of BusinessBusiness WireLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and
2mo agoGCTKGlucotrack, Inc. Announces Reverse Stock SplitBusiness Wire1-for-15 reverse stock split to become effective as of the opening of trading on August 31, 2026 Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a healthcare technology and
2mo agoGCTKLōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100Business WireOne year of work focused on one goal: manufacturing clinical material to enable once-weekly dosingLōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that it has started its
2mo agoGCTKLōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of GeorgiaBusiness WireLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced the continued participation of the University of Georgia’s Student Industry Fellows Program in the ai² Futures Lab™. The renewed
2mo agoGCTKGlucotrack Achieves Key Compliance Milestone and Advances Strategic TransformationBusiness WireGlucotrack, Inc. (NASDAQ:GCTK) today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on The Nasdaq Stock Market, subject to certain conditions. The Panel has
3mo agoGCTKE.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for GlucotrackGlobeNewswireNEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in
3mo agoGCTKGlucotrack Announces $5.5 Million FinancingBusiness WireIncludes $2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium to the market, and $3.5 Million Follow-On Investment from Institutional Investors Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or
3mo agoGCTKCORRECTING and REPLACING Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a PipelineBusiness WireFutures Lab identified 45+ therapeutic opportunities on a $33,000 budget, expands to 13 university partners with 100% retention, and uncovers assets representing more than $500 million in prior industry
3mo agoGCTKLōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection AdministrationBusiness WireFDA Type C Meeting and Nonclinical Study Advance Strategy to Transition LT-100 from 15 Injections to One Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced
3mo agoGCTKE.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note FinancingGlobeNewswireNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the
3mo agoGCTKGlucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets InitiativesGlobeNewswireRUTHERFORD, N.J. and SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™
3mo agoGCTKUPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public PlatformGlobeNewswireRUTHERFORD, N.J. and LA JOLLA, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a
4mo agoGCTKGlucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public PlatformGlobeNewswireRUTHERFORD, N.J. and LA JOLLA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) today announced the completion of its strategic business combination with Lōkahi Therapeutics, establishing a
4mo agoGCTKGlucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM PlatformGlobeNewswireRUTHERFORD, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. ("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical technology company focused on the design, development, and
5mo agoGCTKGlucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific SessionsGlobeNewswireRUTHERFORD, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel
6mo agoGCTKGlucotrack Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireSubmitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology
6mo agoGCTKGlucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring TechnologyGlobeNewswireRUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel
6mo agoGCTKGlucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring TechnologyGlobeNewswireRUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel
6mo agoGCTKGlucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring TechnologyGlobeNewswireRUTHERFORD, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel
7mo agoGCTKGlucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireCompany prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack's
7mo agoGCTKGlucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 MilestonesGlobeNewswireRUTHERFORD, N.J., March 27, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel
8mo agoGCTKGlucotrack to Present at LSI USA '26 Medtech Innovation SummitGlobeNewswireRUTHERFORD, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel
9mo agoGCTKGlucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM PlatformGlobeNewswireRUTHERFORD, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel
10mo agoGCTKGlucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional InvestorGlobeNewswireRutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) (the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people
12mo agoGCTKGlucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate HighlightsGlobeNewswireCompany to submit Investigational Device Exemption (IDE) to FDA for novel CBGM technology in Spring 2026 Expanded clinical advisory team with appointment of pain management and medical technology expert, Usman Latif,
1y agoGCTKGlucotrack, Inc. Encourages Shareholders to VoteGlobeNewswireThe Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.
1y agoGCTKGlucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory TeamGlobeNewswireRUTHERFORD, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.("Glucotrack", or the "Company") (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel
1y agoGCTKGlucotrack, Inc. Reminds Shareholders to VoteGlobeNewswireThe Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc.
1y agoGCTKGlucotrack to Participate in the Q3 Virtual Investor SummitGlobeNewswireRUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel
1y agoGCTKGlucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireOn track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission
1y agoGCTKGlucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, CardiologyGlobeNewswireRUTHERFORD, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes,
1y agoGCTKGlucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual MeetingGlobeNewswireRUTHERFORD, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes,
1y agoGCTKGlucotrack Announces Repurchase of Series A WarrantsGlobeNewswireRUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes,
1y agoGCTKGlucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific SessionsGlobeNewswireRUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with
1y agoGCTKGlucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing RequirementsGlobeNewswire1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a
1y agoGCTKGlucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific SessionsGlobeNewswireGlucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement
1y agoGCTK RBOTGlucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhDGlobeNewswireRUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes,
1y agoGCTKGlucotrack Establishes Patient Advisory Board to Inform Diabetes Technology DevelopmentGlobeNewswireRUTHERFORD, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes,
1y agoGCTKGlucotrack Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireOn track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE)